Patterns and correlates of prostate cancer treatment in older men

Calpurnyia B. Roberts, Peter C. Albertsen, Yu Hsuan Shao, Dirk F. Moore, Amit R. Mehta, Mark N. Stein, Grace L. Lu-Yao

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Although elderly men, particularly patients with low-risk prostate cancer and a life expectancy less than 10 years, are unlikely to benefit from prostate cancer active therapy, treatment rates in this group are high. Methods: By using the population-based Surveillance, Epidemiology, and End Results program linked to Medicare data from 2004 to 2005, we examined the effects of clinical and nonclinical factors on the selection of prostate cancer active therapy (ie, radical prostatectomy, external beam radiation therapy, brachytherapy, or androgen deprivation therapy) in men aged <75 years with a new diagnosis of localized prostate cancer. Multivariate logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for receiving prostate cancer active therapy. Results: The majority of men aged <75 years were treated with prostate cancer active therapy (81.7%), which varied by disease risk level: low, 72.2%; intermediate, 83.7%; and high, 86.4%. Overall, in older men, the percentage of the total variance in the use of prostate cancer active therapy attributable to clinical and nonclinical factors was minimal, 5.1% and 2.6%, respectively. In men with low-risk disease, comorbidity status did not affect treatment selection, such that patients with 1 or 2+ comorbidities were as likely to receive prostate cancer active therapy as healthy men: OR = 0.98; 95% CI, 0.76-1.27 and OR = 1.19; 95% CI, 0.84-1.68, respectively. Geographic location was the most powerful predictor of treatment selection (Northeast vs Greater California: OR = 2.41; 95% CI, 1.75-3.32). Conclusion: Clinical factors play a limited role in treatment selection among elderly patients with localized prostate cancer.

Original languageEnglish
Pages (from-to)235-243
Number of pages9
JournalAmerican Journal of Medicine
Volume124
Issue number3
DOIs
Publication statusPublished - Mar 2011
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Odds Ratio
Therapeutics
Confidence Intervals
Comorbidity
Population Surveillance
SEER Program
Geographic Locations
Brachytherapy
Prostatectomy
Medicare
Life Expectancy
Patient Selection
Androgens
Radiotherapy
Logistic Models

Keywords

  • Aged
  • End Results program
  • Epidemiology
  • Medicare
  • Prostatic neoplasms
  • Region
  • Surveillance
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roberts, C. B., Albertsen, P. C., Shao, Y. H., Moore, D. F., Mehta, A. R., Stein, M. N., & Lu-Yao, G. L. (2011). Patterns and correlates of prostate cancer treatment in older men. American Journal of Medicine, 124(3), 235-243. https://doi.org/10.1016/j.amjmed.2010.10.016

Patterns and correlates of prostate cancer treatment in older men. / Roberts, Calpurnyia B.; Albertsen, Peter C.; Shao, Yu Hsuan; Moore, Dirk F.; Mehta, Amit R.; Stein, Mark N.; Lu-Yao, Grace L.

In: American Journal of Medicine, Vol. 124, No. 3, 03.2011, p. 235-243.

Research output: Contribution to journalArticle

Roberts, CB, Albertsen, PC, Shao, YH, Moore, DF, Mehta, AR, Stein, MN & Lu-Yao, GL 2011, 'Patterns and correlates of prostate cancer treatment in older men', American Journal of Medicine, vol. 124, no. 3, pp. 235-243. https://doi.org/10.1016/j.amjmed.2010.10.016
Roberts, Calpurnyia B. ; Albertsen, Peter C. ; Shao, Yu Hsuan ; Moore, Dirk F. ; Mehta, Amit R. ; Stein, Mark N. ; Lu-Yao, Grace L. / Patterns and correlates of prostate cancer treatment in older men. In: American Journal of Medicine. 2011 ; Vol. 124, No. 3. pp. 235-243.
@article{f9758df2689e428d8b0070caa6eb381e,
title = "Patterns and correlates of prostate cancer treatment in older men",
abstract = "Background: Although elderly men, particularly patients with low-risk prostate cancer and a life expectancy less than 10 years, are unlikely to benefit from prostate cancer active therapy, treatment rates in this group are high. Methods: By using the population-based Surveillance, Epidemiology, and End Results program linked to Medicare data from 2004 to 2005, we examined the effects of clinical and nonclinical factors on the selection of prostate cancer active therapy (ie, radical prostatectomy, external beam radiation therapy, brachytherapy, or androgen deprivation therapy) in men aged <75 years with a new diagnosis of localized prostate cancer. Multivariate logistic regression was used to estimate odds ratios (ORs) and 95{\%} confidence intervals (CIs) for receiving prostate cancer active therapy. Results: The majority of men aged <75 years were treated with prostate cancer active therapy (81.7{\%}), which varied by disease risk level: low, 72.2{\%}; intermediate, 83.7{\%}; and high, 86.4{\%}. Overall, in older men, the percentage of the total variance in the use of prostate cancer active therapy attributable to clinical and nonclinical factors was minimal, 5.1{\%} and 2.6{\%}, respectively. In men with low-risk disease, comorbidity status did not affect treatment selection, such that patients with 1 or 2+ comorbidities were as likely to receive prostate cancer active therapy as healthy men: OR = 0.98; 95{\%} CI, 0.76-1.27 and OR = 1.19; 95{\%} CI, 0.84-1.68, respectively. Geographic location was the most powerful predictor of treatment selection (Northeast vs Greater California: OR = 2.41; 95{\%} CI, 1.75-3.32). Conclusion: Clinical factors play a limited role in treatment selection among elderly patients with localized prostate cancer.",
keywords = "Aged, End Results program, Epidemiology, Medicare, Prostatic neoplasms, Region, Surveillance, Treatment",
author = "Roberts, {Calpurnyia B.} and Albertsen, {Peter C.} and Shao, {Yu Hsuan} and Moore, {Dirk F.} and Mehta, {Amit R.} and Stein, {Mark N.} and Lu-Yao, {Grace L.}",
year = "2011",
month = "3",
doi = "10.1016/j.amjmed.2010.10.016",
language = "English",
volume = "124",
pages = "235--243",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Patterns and correlates of prostate cancer treatment in older men

AU - Roberts, Calpurnyia B.

AU - Albertsen, Peter C.

AU - Shao, Yu Hsuan

AU - Moore, Dirk F.

AU - Mehta, Amit R.

AU - Stein, Mark N.

AU - Lu-Yao, Grace L.

PY - 2011/3

Y1 - 2011/3

N2 - Background: Although elderly men, particularly patients with low-risk prostate cancer and a life expectancy less than 10 years, are unlikely to benefit from prostate cancer active therapy, treatment rates in this group are high. Methods: By using the population-based Surveillance, Epidemiology, and End Results program linked to Medicare data from 2004 to 2005, we examined the effects of clinical and nonclinical factors on the selection of prostate cancer active therapy (ie, radical prostatectomy, external beam radiation therapy, brachytherapy, or androgen deprivation therapy) in men aged <75 years with a new diagnosis of localized prostate cancer. Multivariate logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for receiving prostate cancer active therapy. Results: The majority of men aged <75 years were treated with prostate cancer active therapy (81.7%), which varied by disease risk level: low, 72.2%; intermediate, 83.7%; and high, 86.4%. Overall, in older men, the percentage of the total variance in the use of prostate cancer active therapy attributable to clinical and nonclinical factors was minimal, 5.1% and 2.6%, respectively. In men with low-risk disease, comorbidity status did not affect treatment selection, such that patients with 1 or 2+ comorbidities were as likely to receive prostate cancer active therapy as healthy men: OR = 0.98; 95% CI, 0.76-1.27 and OR = 1.19; 95% CI, 0.84-1.68, respectively. Geographic location was the most powerful predictor of treatment selection (Northeast vs Greater California: OR = 2.41; 95% CI, 1.75-3.32). Conclusion: Clinical factors play a limited role in treatment selection among elderly patients with localized prostate cancer.

AB - Background: Although elderly men, particularly patients with low-risk prostate cancer and a life expectancy less than 10 years, are unlikely to benefit from prostate cancer active therapy, treatment rates in this group are high. Methods: By using the population-based Surveillance, Epidemiology, and End Results program linked to Medicare data from 2004 to 2005, we examined the effects of clinical and nonclinical factors on the selection of prostate cancer active therapy (ie, radical prostatectomy, external beam radiation therapy, brachytherapy, or androgen deprivation therapy) in men aged <75 years with a new diagnosis of localized prostate cancer. Multivariate logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for receiving prostate cancer active therapy. Results: The majority of men aged <75 years were treated with prostate cancer active therapy (81.7%), which varied by disease risk level: low, 72.2%; intermediate, 83.7%; and high, 86.4%. Overall, in older men, the percentage of the total variance in the use of prostate cancer active therapy attributable to clinical and nonclinical factors was minimal, 5.1% and 2.6%, respectively. In men with low-risk disease, comorbidity status did not affect treatment selection, such that patients with 1 or 2+ comorbidities were as likely to receive prostate cancer active therapy as healthy men: OR = 0.98; 95% CI, 0.76-1.27 and OR = 1.19; 95% CI, 0.84-1.68, respectively. Geographic location was the most powerful predictor of treatment selection (Northeast vs Greater California: OR = 2.41; 95% CI, 1.75-3.32). Conclusion: Clinical factors play a limited role in treatment selection among elderly patients with localized prostate cancer.

KW - Aged

KW - End Results program

KW - Epidemiology

KW - Medicare

KW - Prostatic neoplasms

KW - Region

KW - Surveillance

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=79952479958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952479958&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2010.10.016

DO - 10.1016/j.amjmed.2010.10.016

M3 - Article

C2 - 21396507

AN - SCOPUS:79952479958

VL - 124

SP - 235

EP - 243

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -